Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decline in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 700 shares, a decrease of 99.0% from the December 15th total of 68,200 shares. Based on an average trading volume of 82,000 shares, the short-interest ratio is presently 0.0 days.

Apollomics Trading Up 14.7 %

APLMW opened at $0.01 on Tuesday. The firm’s 50 day moving average is $0.01 and its 200-day moving average is $0.01. Apollomics has a 52-week low of $0.01 and a 52-week high of $0.04.

About Apollomics

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.